Corrigendum to ‘detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives’

Hingrat, Quentin Le; Visseaux, Benoît; Laouénan, Cédric; Tubiana, Sarah; Bouadma, Lila; Yazdanpanah, Yazdan; Duval, Xavier; Burdet, Charles; Ichou, Houria; Damond, Florence; Bertine, Mélanie; Benmalek, Nabil; Choquet, Christophe; Timsit, Jean‐François; Ghosn, Jade; Charpentier, Charlotte; Descamps, Diane; Houhou‐Fidouh, Nadhira

doi:10.1016/j.cmi.2021.09.034

Cited by 18 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the sensitivity value of COVID-VIRO on NP samples with Cts ≤33 was 86% (CI 95%: 79−90.5%). These results are comparable to those of Hingrat et al that showed that with high nasopharyngeal viral loads, i.e., Ct values below 30 and 33, only 1/50 and 4/67 tested negative for N-antigenaemia, respectively [ 16 ]. In addition, they have shown this with hospitalized patients with symptoms compatible with SARS-CoV-2 infection, but with a negative nasopharyngeal RT-PCR, 8/12 presented positive N-antigenaemia.…”

Section: Discussionsupporting

confidence: 88%

“…N-antigenemia levels were determined from serum samples with a CE-IVD ELISA microplate assay, the COV-QUANTO kit (AAZ, Boulogne-Billancourt, France), following manufacturer instructions. This assay has been evaluated elsewhere [ 11 , 16 ]. The cut-off limit was presented at 2.98 pg/mL, according to manufacturer recommendations.…”

Section: Methodsmentioning

confidence: 99%

“…Li et al analyzed 50 cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients, observing an N protein positivity rate of 76%, suggesting that the serum measurement of SARS-CoV-2 N protein by ELISA can have high diagnostic value for infected patients before the antibody appears, thus shortening the window of serological diagnosis [ 15 ]. Other studies have demonstrated N-Ag in blood (serum and plasma) as an interesting biomarker for SARS-CoV-2 infection [ 16 , 17 , 18 ], with diagnostic sensitivity and specificity of ELISA reaching 81.4% and 99.8%, respectively [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Added Value of SARS-CoV-2 Antigen Detection in Blood Samples

et al. 2022

View full text Add to dashboard Cite

This study evaluated the performances of immunoassays (LFIA and ELISA) designed for SARS-CoV-2 Antigen (Ag)-detection in nasopharyngeal (NP) and serum samples in comparison to RT-PCR. NP samples from patients with respiratory symptoms (183 RT-PCR-positive and 74 RT-PCR-negative samples) were collected from March to April and November to December 2020. Seroconversion and antigen dynamics were assessed by symptom onset and day of RT-PCR diagnosis. Serum samples from 87 COVID-19 patients were used to investigate the added value of Ag quantification, at diagnosis and during follow-up. The sensitivity of COVID-VIRO-LFIA on samples with Ct ≤ 33, considered as the contagious threshold, was 86% on NPs (CI 95%: 79–90.5) and 76% on serum samples (CI 95%: 59.4–88), with a specificity of 100%. Serum N-Ag was detected during active infection as early as day two from symptom onset, with a diagnostic sensitivity of 81.5%. Within one week of symptom onset, diagnostic sensitivity and specificity reached 90.9% (95% CI, 85.1%–94.6%) and 98.3% (95% CI, 91.1%–99.9%), respectively. Serum N-Ag concentration closely correlated with disease severity. Longitudinal analysis revealed the simultaneous increase of antibodies and decrease of N-Ag. Sensitivities of COVID-VIRO-LFIA and COV-QUANTO-ELISA tests on NP and serum samples were close to 80%. They are suitable COVID-19-laboratory diagnostic tests, particularly when blood samples are available, thus reducing the requirement for NP sampling, and subsequent PCR analysis. ELISA titers may help to identify patients at risk of poor outcomes.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Added Value of SARS-CoV-2 Antigen Detection in Blood Samples

et al. 2022

View full text Add to dashboard Cite

show abstract

“…SARS-CoV-2 proteins in the blood (antigenemia) of individuals with COVID-19 have been well described in adults but limited data are available for children, in whom clinical manifestations of SARS-CoV-2 infection are more heterogeneous. Viral nucleocapsid antigenemia has been identified as a sensitive and specific biomarker of acute infection, [1][2][3][4][5] and both nucleocapsid and spike antigenemia have been associated with disease severity in adults. [3][4][5] Spike protein antigenemia has also been inconsistently observed in children with SARS-CoV-2 associated multisystem inflammatory syndrome (MIS-C).…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 Antigenemia is Associated With Pneumonia in Children But Lacks Sensitivity to Diagnose Acute Infection

Damhorst

Verkerke

Harrington

et al. 2022

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Background: Nucleocapsid antigenemia in adults has demonstrated high sensitivity and specificity for acute infection, and antigen burden is associated with disease severity. Data regarding SARS-CoV-2 antigenemia in children are limited. Methods: We retrospectively analyzed blood plasma specimens from hospitalized children with COVID-19 or MIS-C. Nucleocapsid and spike were measured using ultrasensitive immunoassays. Results: We detected nucleocapsid antigenemia in 62% (50/81) and spike antigenemia in 27% (21/79) of children with acute COVID-19 but 0% (0/26) and 15% (4/26) with MIS-C from March 2020–March 2021. Higher nucleocapsid levels were associated with radiographic infiltrates and respiratory symptoms in children with COVID-19. Conclusions: Antigenemia lacks the sensitivity to diagnose acute infection in children but is associated with signs and symptoms of lower respiratory tract involvement. Further study into the mechanism of antigenemia, its association with specific organ involvement, and the role of antigenemia in the pathogenesis of COVID-19 is warranted.

show abstract

“…Circulation of viral antigens in blood is a mainstay of diagnostic testing in systemic viral infections, for example, HBV and HIV. However, in respiratory infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), antigenemia in serum is harder to interpret 1,2 . Systemic presence of nucleocapsid (NCP), as well as spike (S) protein, has been described 3 .…”

Section: Introductionmentioning

confidence: 99%

Impaired systemic nucleocapsid antigen clearance in severe COVID‐19

Bauer

Mack

Hefter

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

The circulating nucleocapsid (NCP) antigen of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is detectable in coronavirus disease‐2019 (COVID‐19) patients. To better understand the biology of disease severity, we investigated NCP clearance kinetics in hospitalized COVID‐19 patients. Serum NCP was quantified using a commercial NCP‐specific enzyme‐linked immunoassay in hospitalized COVID‐19 patients (n = 63) during their hospital stay. Results were correlated to COVID‐19 disease severity, inflammation parameters, antibody response, and results of SARS‐CoV‐2 PCR from nasopharyngeal swabs. We demonstrate that NCP antigen levels in serum remained elevated in 21/45 (46.7%) samples from patients in intensive care units (ICU) after >8 days postdiagnosis. The proportion of ICU patients with detectable antigenemia declined only gradually from 84.6% to 25.0% over several weeks. This was in contrast to complete NCP clearance in all non‐ICU patients after 8 days, and also in contrast to mucosal clearance of the virus as measured by PCR. Antigen clearance was associated with higher IgG against S1 but not NCP. Clearance of NCP antigenemia is delayed in >40% of severely ill COVID‐19 patients. Thus, NCP antigenemia detected after 8 days post COVID‐19 diagnosis is a characteristic of patients requiring intensive care. Prospective trials should further investigate NCP antigen clearance kinetics as a mechanistic biomarker.

show abstract

Corrigendum to ‘detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives’

Abstract: Clinical Microbiology and Infection xxx (xxxx) xxx Please cite this article as: Le Hingrat Q et al., Corrigendum to 'detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives', Clinical Microbiology and Infection,

Cited by 18 publications

References 0 publications

Clinical Added Value of SARS-CoV-2 Antigen Detection in Blood Samples

Clinical Added Value of SARS-CoV-2 Antigen Detection in Blood Samples

SARS-CoV-2 Antigenemia is Associated With Pneumonia in Children But Lacks Sensitivity to Diagnose Acute Infection

Impaired systemic nucleocapsid antigen clearance in severe COVID‐19

Contact Info

Product

Resources

About